• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

KK-LC-1，一种原发性肝癌免疫治疗预后的生物标志物。

KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer.

机构信息

Comprehensive Cancer Centre, Department of Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

Comprehensive Cancer Centre of Nanjing international Hospital, Medical School of Nanjing University, Nanjing, China.

出版信息

BMC Cancer. 2024 Jul 7;24(1):811. doi: 10.1186/s12885-024-12586-y.

DOI:10.1186/s12885-024-12586-y
PMID:38972967
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11229184/
Abstract

PURPOSE

There is mounting evidence that patients with liver cancer can benefit from Immune checkpoint inhibitors. However, due to the high cost and low efficacy, we aimed to explore new biomarkers for predicting the efficacy of immunotherapy.

METHODS

Specimens and medical records of liver cancer patients treated at Drum Tower Hospital of Nanjing University were collected, and the expression of Kita-Kyushu lung cancer antigen-1 (KK-LC-1) in tissues as well as the corresponding antibodies in serum were examined to find biomarkers related to the prognosis of immunotherapy and to explore its mechanism in the development of liver cancer.

RESULTS

KK-LC-1 expression was found to be 34.4% in histopathological specimens from 131 patients and was significantly correlated with Foxp3 expression (P = 0.0356). The expression of Foxp3 in the tissues of 24 patients who received immunotherapy was significantly correlated with overall survival (OS) (P = 0.0247), and there was also a tendency for prolonged OS in patients with high expression of KK-LC-1. In addition, the expression of KK-LC-1 antibody in the serum of patients who received immunotherapy with a first efficacy evaluation of stable disease (SD) was significantly higher than those with partial response (PR) (P = 0.0413).

CONCLUSIONS

Expression of KK-LC-1 in both tissues and serum has been shown to correlate with the prognosis of patients treated with immunotherapy, and KK-LC-1 is a potential therapeutic target for oncological immunotherapy.

摘要

目的

越来越多的证据表明肝癌患者可以从免疫检查点抑制剂中获益。然而，由于成本高、疗效低，我们旨在探索新的生物标志物来预测免疫治疗的疗效。

方法

收集南京大学鼓楼医院肝癌患者的标本和病历，检测组织中 Kita-Kyushu 肺癌抗原-1（KK-LC-1）的表达以及血清中相应的抗体，寻找与免疫治疗预后相关的生物标志物，并探讨其在肝癌发展中的机制。

结果

在 131 例患者的组织病理学标本中发现 KK-LC-1 表达率为 34.4%，与 Foxp3 表达显著相关（P=0.0356）。24 例接受免疫治疗患者的组织中 Foxp3 的表达与总生存期（OS）显著相关（P=0.0247），KK-LC-1 高表达的患者 OS 也有延长的趋势。此外，首次疗效评估为稳定疾病（SD）的接受免疫治疗的患者血清中 KK-LC-1 抗体的表达明显高于部分反应（PR）（P=0.0413）。

结论

组织和血清中 KK-LC-1 的表达与免疫治疗患者的预后相关，KK-LC-1 是肿瘤免疫治疗的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/00676c46b766/12885_2024_12586_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/c187e1ce5fcf/12885_2024_12586_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/4b04d11b3403/12885_2024_12586_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/ad1f938b5425/12885_2024_12586_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/a2e48f292fa1/12885_2024_12586_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/00676c46b766/12885_2024_12586_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/c187e1ce5fcf/12885_2024_12586_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/4b04d11b3403/12885_2024_12586_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/ad1f938b5425/12885_2024_12586_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/a2e48f292fa1/12885_2024_12586_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba98/11229184/00676c46b766/12885_2024_12586_Fig5_HTML.jpg

相似文献

1
KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer.KK-LC-1，一种原发性肝癌免疫治疗预后的生物标志物。
BMC Cancer. 2024 Jul 7;24(1):811. doi: 10.1186/s12885-024-12586-y.
2
KK-LC-1 may be an effective prognostic biomarker for gastric cancer.KK-LC-1 可能是胃癌的一种有效预后生物标志物。
BMC Cancer. 2021 Mar 12;21(1):267. doi: 10.1186/s12885-021-07974-7.
3
Cancer/testis antigen, Kita-Kyushu lung cancer antigen-1 and ABCD stratification for diagnosing gastric cancers.癌症/睾丸抗原、北九州肺癌抗原 1 和 ABCD 分层在胃癌诊断中的应用。
World J Gastroenterol. 2020 Jan 28;26(4):424-432. doi: 10.3748/wjg.v26.i4.424.
4
Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer.北九州肺癌抗原-1（KK-LC-1）在胃癌中频繁高表达。
Anticancer Res. 2015 Jun;35(6):3575-9.
5
Cancer-testis antigen KK-LC-1 is a potential biomarker associated with immune cell infiltration in lung adenocarcinoma.癌-睾丸抗原 KK-LC-1 是与肺腺癌免疫细胞浸润相关的潜在生物标志物。
BMC Cancer. 2022 Jul 30;22(1):834. doi: 10.1186/s12885-022-09930-5.
6
Detection of KK-LC-1 Protein, a Cancer/Testis Antigen, in Patients with Breast Cancer.乳腺癌患者中癌/睾丸抗原KK-LC-1蛋白的检测
Anticancer Res. 2018 Oct;38(10):5923-5928. doi: 10.21873/anticanres.12937.
7
Hypomethylation-mediated activation of cancer/testis antigen KK-LC-1 facilitates hepatocellular carcinoma progression through activating the Notch1/Hes1 signalling.低甲基化介导的癌症/睾丸抗原 KK-LC-1 的激活通过激活 Notch1/Hes1 信号促进肝癌进展。
Cell Prolif. 2019 May;52(3):e12581. doi: 10.1111/cpr.12581. Epub 2019 Mar 20.
8
Correlation Between Expression of the Cancer/Testis Antigen KK-LC-1 and Infection in Gastric Cancer.癌胚抗原KK-LC-1的表达与胃癌感染之间的相关性
In Vivo. 2017 May-Jun;31(3):403-407. doi: 10.21873/invivo.11073.
9
DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.DNA 损伤修复状态预测肝癌免疫治疗和非免疫治疗的相反临床预后。
Front Immunol. 2021 Jul 15;12:676922. doi: 10.3389/fimmu.2021.676922. eCollection 2021.
10
Early gastric cancer frequently has high expression of KK-LC-1, a cancer-testis antigen.早期胃癌常有 KK-LC-1 的高表达，这是一种癌-睾丸抗原。
World J Gastroenterol. 2017 Dec 14;23(46):8200-8206. doi: 10.3748/wjg.v23.i46.8200.

引用本文的文献

1
Advances and challenges in molecular understanding, early detection, and targeted treatment of liver cancer.肝癌分子认识、早期检测及靶向治疗的进展与挑战
World J Hepatol. 2025 Jan 27;17(1):102273. doi: 10.4254/wjh.v17.i1.102273.

本文引用的文献

1
Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review.癌症疫苗治疗学：局限性和有效性——文献综述。
Cells. 2023 Aug 28;12(17):2159. doi: 10.3390/cells12172159.
2
Cancer-testis antigen KK-LC-1 is a potential biomarker associated with immune cell infiltration in lung adenocarcinoma.癌-睾丸抗原 KK-LC-1 是与肺腺癌免疫细胞浸润相关的潜在生物标志物。
BMC Cancer. 2022 Jul 30;22(1):834. doi: 10.1186/s12885-022-09930-5.
3
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.免疫检查点抑制剂的肿瘤免疫疗法；优缺点。
Cell Commun Signal. 2022 Apr 7;20(1):44. doi: 10.1186/s12964-022-00854-y.
4
Cancer statistics for the year 2020: An overview.2020年癌症统计数据概述。
Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588.
5
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
6
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.抗 PD-1 治疗期间晚期肝细胞癌患者的超进展性疾病。
J Hepatol. 2021 Feb;74(2):350-359. doi: 10.1016/j.jhep.2020.08.010. Epub 2020 Aug 15.
7
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.多抗原靶向 T 细胞疗法治疗多发性骨髓瘤患者的安全性和临床效果。
Sci Transl Med. 2020 Jul 29;12(554). doi: 10.1126/scitranslmed.aaz3339.
8
Diagnostic and prognostic value of the cancer-testis antigen lactate dehydrogenase C4 in breast cancer.乳腺癌中癌-睾丸抗原乳酸脱氢酶 C4 的诊断和预后价值。
Clin Chim Acta. 2020 Apr;503:203-209. doi: 10.1016/j.cca.2019.11.032. Epub 2019 Nov 30.
9
Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.晚期肝细胞癌中已确立和新出现的免疫检查点抑制剂反应生物标志物的患病率
Oncotarget. 2019 Jun 18;10(40):4018-4025. doi: 10.18632/oncotarget.26998.
10
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study.肝细胞癌 PD-L1 免疫组化检测异质性的临床意义：Blueprint-HCC 研究。
Br J Cancer. 2019 May;120(11):1033-1036. doi: 10.1038/s41416-019-0466-x. Epub 2019 May 7.